Targeting SOX2+ cancer cells could be a strong therapeutic strategy to expunge CSCs and the approach requires bona fide study because SOX2 is also expressed in normal stem cells, and in general, SOX2+ tumor cells remain quiescent. Here, SOX2 is linked to neoplasm.